Litong Nie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Litong Nie has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Junjie Chen
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
15 shared publications Chao Wang
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030
9 shared publicationsMengfan Tang
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
7 shared publicationsMin Huang
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030
6 shared publicationsXu Feng
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publicationsHuimin Zhang
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030
5 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (12)
CHD1L maintains genome integrity by facilitating okazaki fragment maturation
The dynamic synthesis and removal of poly (ADP-ribose) (pADPr) by poly (ADP-ribose) polymerase 1 and poly (ADP-ribose) glycohydrolase (PARG), respectively, is essential for the maintenance of genome integrity, particularly during DNA replication. However, the precise role of the pADPr-binding chromatin remodeler chromodomain helicase DNA binding protein 1-like (CHD1L) in resolving endogenous DNA damage remains unclear. Here, we identified CHD1L as a critical modulator of Okazaki fragment maturation. We demonstrated that CHD1L loss was synthetic lethal with severe inhibition of PARG. This synthetic lethality stemmed from the toxic accumulation of pADPr specifically in S-phase cells, originating from unprocessed Okazaki fragment intermediates. Rescue experiments confirmed that both the ATPase and pADPr-binding macrodomain of CHD1L were indispensable for preventing this toxic accumulation. Mechanistically, quantitative chromatin proteomics revealed that CHD1L deficiency caused the persistent and aberrant retention of single-strand break (SSB) repair factors and others including the E3 ubiquitin ligases RNF114 and DTX3L/PARP9, challenging the previous models that CHD1L loss would limit chromatin accessibility of DNA repair factors. These findings establish a novel housekeeping function for CHD1L in facilitating the efficient turnover of DNA repair factors at replication-associated SSBs.
- 22 June 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (12)
Open AccessCHD1L maintains genome integrity by facilitating okazaki fragment maturation
The dynamic synthesis and removal of poly (ADP-ribose) (pADPr) by poly (ADP-ribose) polymerase 1 and poly (ADP-ribose) glycohydrolase (PARG), respectively, is essential for the maintenance of genome integrity, particularly during DNA replication. However, the precise role of the pADPr-binding chromatin remodeler chromodomain helicase DNA binding protein 1-like (CHD1L) in resolving endogenous DNA damage remains unclear. Here, we identified CHD1L as a critical modulator of Okazaki fragment maturation. We demonstrated that CHD1L loss was synthetic lethal with severe inhibition of PARG. This synthetic lethality stemmed from the toxic accumulation of pADPr specifically in S-phase cells, originating from unprocessed Okazaki fragment intermediates. Rescue experiments confirmed that both the ATPase and pADPr-binding macrodomain of CHD1L were indispensable for preventing this toxic accumulation. Mechanistically, quantitative chromatin proteomics revealed that CHD1L deficiency caused the persistent and aberrant retention of single-strand break (SSB) repair factors and others including the E3 ubiquitin ligases RNF114 and DTX3L/PARP9, challenging the previous models that CHD1L loss would limit chromatin accessibility of DNA repair factors. These findings establish a novel housekeeping function for CHD1L in facilitating the efficient turnover of DNA repair factors at replication-associated SSBs.
- Open Access
- 26 March 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
CHK1 is an integral regulator of DNA replication in human cells
CHK1, a key serine/threonine kinase, is essential for cell cycle progression and genome maintenance in response to DNA damage and/or replication stress. However, its functions during normal DNA replication remain to be defined. Here, we employed the dTAG system to achieve rapid and selective CHK1 depletion in cells and examined the consequences of its acute loss. CHK1 degradation led to rapid cell death, with significant loss of viability within 16 h and complete lethality by 48 h, indicating critical roles of CHK1 during normal DNA replication. Rescue experiments demonstrated that only full-length, catalytically active CHK1 could restore cell survival, emphasizing the essential role of its kinase function and ATR-dependent phosphorylation. CHK1 depletion triggered extensive DNA damage, as evidenced by increased γH2AX and RPA2 phosphorylation, and caused S-phase arrest, replication fork collapse, and failure to enter mitosis. Interestingly, cells arrested at the G1/S boundary, which do not undergo DNA replication, were still sensitive to CHK1 depletion. These data reveal a critical role of CHK1 in suppressing replication fork progression even in the absence of DNA replication. Thus, our results highlight CHK1’s indispensable role in the management of replication fork stability and cell cycle progression, providing a refined mechanistic understanding of its function during normal cell proliferation.
- 26 March 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessCHK1 is an integral regulator of DNA replication in human cells
CHK1, a key serine/threonine kinase, is essential for cell cycle progression and genome maintenance in response to DNA damage and/or replication stress. However, its functions during normal DNA replication remain to be defined. Here, we employed the dTAG system to achieve rapid and selective CHK1 depletion in cells and examined the consequences of its acute loss. CHK1 degradation led to rapid cell death, with significant loss of viability within 16 h and complete lethality by 48 h, indicating critical roles of CHK1 during normal DNA replication. Rescue experiments demonstrated that only full-length, catalytically active CHK1 could restore cell survival, emphasizing the essential role of its kinase function and ATR-dependent phosphorylation. CHK1 depletion triggered extensive DNA damage, as evidenced by increased γH2AX and RPA2 phosphorylation, and caused S-phase arrest, replication fork collapse, and failure to enter mitosis. Interestingly, cells arrested at the G1/S boundary, which do not undergo DNA replication, were still sensitive to CHK1 depletion. These data reveal a critical role of CHK1 in suppressing replication fork progression even in the absence of DNA replication. Thus, our results highlight CHK1’s indispensable role in the management of replication fork stability and cell cycle progression, providing a refined mechanistic understanding of its function during normal cell proliferation.
- 21 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (799) , eado7225
In vivo CRISPR activation screen identifies acyl-CoA–binding protein as a driver of bone metastasis
One of the most common sites of cancer metastasis is to the bone. Bone metastasis is associated with substantial morbidity and mortality, and current therapeutic interventions remain largely palliative. Metastasizing tumor cells need to reprogram their metabolic states to adapt to the nutrient environment of distant organs; however, the role and translational relevance of lipid metabolism in bone metastasis remain unclear. Here, we used an in vivo CRISPR activation screening system coupled with positive selection to identify acyl–coenzyme A (CoA) binding protein (ACBP) as a bone metastasis driver. In nonmetastatic and weakly metastatic cancer cells, overexpression of wild-type ACBP, but not the acyl-CoA–binding deficient mutant, stimulated fatty acid oxidation (FAO) and bone metastasis. Conversely, knockout of ACBP in highly bone metastatic cancer cells abrogated metastatic bone colonization. Mechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive oxygen species, and inhibited lipid peroxidation and ferroptosis. We found that ACBP expression correlated with metabolic signaling, bone metastatic ability, and poor clinical outcomes. In mouse models, pharmacological blockade of FAO or treatment with a ferroptosis inducer inhibited bone metastasis. Together, our findings reveal the role of lipid metabolism in tumor cells adapting and thriving in the bone and identify ACBP as a key regulator of this process. Agents that target FAO or induce ferroptosis represent a promising therapeutic approach for treating bone metastases.
- 21 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (799) , eado7225
In vivo CRISPR activation screen identifies acyl-CoA–binding protein as a driver of bone metastasis
One of the most common sites of cancer metastasis is to the bone. Bone metastasis is associated with substantial morbidity and mortality, and current therapeutic interventions remain largely palliative. Metastasizing tumor cells need to reprogram their metabolic states to adapt to the nutrient environment of distant organs; however, the role and translational relevance of lipid metabolism in bone metastasis remain unclear. Here, we used an in vivo CRISPR activation screening system coupled with positive selection to identify acyl–coenzyme A (CoA) binding protein (ACBP) as a bone metastasis driver. In nonmetastatic and weakly metastatic cancer cells, overexpression of wild-type ACBP, but not the acyl-CoA–binding deficient mutant, stimulated fatty acid oxidation (FAO) and bone metastasis. Conversely, knockout of ACBP in highly bone metastatic cancer cells abrogated metastatic bone colonization. Mechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive oxygen species, and inhibited lipid peroxidation and ferroptosis. We found that ACBP expression correlated with metabolic signaling, bone metastatic ability, and poor clinical outcomes. In mouse models, pharmacological blockade of FAO or treatment with a ferroptosis inducer inhibited bone metastasis. Together, our findings reveal the role of lipid metabolism in tumor cells adapting and thriving in the bone and identify ACBP as a key regulator of this process. Agents that target FAO or induce ferroptosis represent a promising therapeutic approach for treating bone metastases.
- Open Access
- 19 September 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (39)
In vivo CRISPR screens identifyMgaas an immunotherapy target in triple-negative breast cancer
Immune evasion is not only critical for tumor initiation and progression, but also determines the efficacy of immunotherapies. Through iterative in vivo CRISPR screens with seven syngeneic tumor models, we identified core and context-dependent immune evasion pathways across cancer types. This valuable high-confidence dataset is available for the further understanding of tumor intrinsic immunomodulators, which may lead to the discovery of effective anticancer therapeutic targets. With a focus on triple-negative breast cancer (TNBC), we found thatMgaknock-out significantly enhances antitumor immunity and inhibits tumor growth. Transcriptomics and single-cell RNA sequencing analyses revealed that Mga influences various immune-related pathways in the tumor microenvironment. Our findings suggest that Mga may play a role in modulating the tumor immune landscape, though the precise mechanisms require further investigation. Interestingly, we observed that low MGA expression in breast cancer patients correlates with a favorable prognosis, particularly in those with active interferon-γ signaling. These observations provide insights into tumor immune escape mechanisms and suggest that further exploration of MGA’s function could potentially lead to effective therapeutic strategies in TNBC.
- 19 September 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (39)
Open AccessIn vivo CRISPR screens identifyMgaas an immunotherapy target in triple-negative breast cancer
Immune evasion is not only critical for tumor initiation and progression, but also determines the efficacy of immunotherapies. Through iterative in vivo CRISPR screens with seven syngeneic tumor models, we identified core and context-dependent immune evasion pathways across cancer types. This valuable high-confidence dataset is available for the further understanding of tumor intrinsic immunomodulators, which may lead to the discovery of effective anticancer therapeutic targets. With a focus on triple-negative breast cancer (TNBC), we found thatMgaknock-out significantly enhances antitumor immunity and inhibits tumor growth. Transcriptomics and single-cell RNA sequencing analyses revealed that Mga influences various immune-related pathways in the tumor microenvironment. Our findings suggest that Mga may play a role in modulating the tumor immune landscape, though the precise mechanisms require further investigation. Interestingly, we observed that low MGA expression in breast cancer patients correlates with a favorable prognosis, particularly in those with active interferon-γ signaling. These observations provide insights into tumor immune escape mechanisms and suggest that further exploration of MGA’s function could potentially lead to effective therapeutic strategies in TNBC.
- 27 July 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (35) , 2621-2634
Systematic investigation of BRCA1-A, -B, and -C complexes and their functions in DNA damage response and DNA repair
BRCA1, a breast cancer susceptibility gene, has emerged as a central mediator that brings together multiple signaling complexes in response to DNA damage. The A, B, and C complexes of BRCA1, which are formed based on their phosphorylation-dependent interactions with the BRCA1-C-terminal domains, contribute to the roles of BRCA1 in DNA repair and cell cycle checkpoint control. However, their functions in DNA damage response remain to be fully appreciated. Specifically, there has been no systematic investigation of the roles of BRCA1-A, -B, and -C complexes in the regulation of BRCA1 localization and functions, in part because of cellular lethality associated with loss of CtIP protein, which is an essential component in BRCA1-C complex. To systematically investigate the functions of these complexes in DNA damage response, we depleted a key component in each of these complexes. We used the degradation tag system to inducibly deplete endogenous CtIP and obtained a series of RAP80/FANCJ/CtIP single-, double-, and triple-knockout cells. We showed that loss of BRCA1-B/FANCJ and BRCA1-C/CtIP, but not BRCA1-A/RAP80, resulted in reduced cell proliferation and increased sensitivity to DNA damage. BRCA1-C/CtIP and BRCA1-A/RAP80 were involved in BRCA1 recruitment to sites of DNA damage. However, BRCA1-A/RAP80 was not essential for damage-induced BRCA1 localization. Instead, RAP80/H2AX and CtIP have redundant roles in BRCA1 recruitment. Altogether, our systematic analysis uncovers functional differences between BRCA1-A, -B, and -C complexes and provides new insights into the roles of these BRCA1-associated protein complexes in DNA damage response and DNA repair.
- 27 July 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (35) , 2621-2634
Systematic investigation of BRCA1-A, -B, and -C complexes and their functions in DNA damage response and DNA repair
BRCA1, a breast cancer susceptibility gene, has emerged as a central mediator that brings together multiple signaling complexes in response to DNA damage. The A, B, and C complexes of BRCA1, which are formed based on their phosphorylation-dependent interactions with the BRCA1-C-terminal domains, contribute to the roles of BRCA1 in DNA repair and cell cycle checkpoint control. However, their functions in DNA damage response remain to be fully appreciated. Specifically, there has been no systematic investigation of the roles of BRCA1-A, -B, and -C complexes in the regulation of BRCA1 localization and functions, in part because of cellular lethality associated with loss of CtIP protein, which is an essential component in BRCA1-C complex. To systematically investigate the functions of these complexes in DNA damage response, we depleted a key component in each of these complexes. We used the degradation tag system to inducibly deplete endogenous CtIP and obtained a series of RAP80/FANCJ/CtIP single-, double-, and triple-knockout cells. We showed that loss of BRCA1-B/FANCJ and BRCA1-C/CtIP, but not BRCA1-A/RAP80, resulted in reduced cell proliferation and increased sensitivity to DNA damage. BRCA1-C/CtIP and BRCA1-A/RAP80 were involved in BRCA1 recruitment to sites of DNA damage. However, BRCA1-A/RAP80 was not essential for damage-induced BRCA1 localization. Instead, RAP80/H2AX and CtIP have redundant roles in BRCA1 recruitment. Altogether, our systematic analysis uncovers functional differences between BRCA1-A, -B, and -C complexes and provides new insights into the roles of these BRCA1-associated protein complexes in DNA damage response and DNA repair.
- Open Access
- 5 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
DePARylation is critical for S phase progression and cell survival
Poly(ADP-ribose)ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation by poly(ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic regulation of DNA damage response. PARG, the most active dePARylation enzyme, is recruited to sites of DNA damage via pADPr-dependent and PCNA-dependent mechanisms. Targeting dePARylation is considered an alternative strategy to overcome PARP inhibitor resistance. However, precisely how dePARylation functions in normal unperturbed cells remains elusive. To address this challenge, we conducted multiple CRISPR screens and revealed that dePARylation of S phase pADPr by PARG is essential for cell viability. Loss of dePARylation activity initially induced S-phase-specific pADPr signaling, which resulted from unligated Okazaki fragments and eventually led to uncontrolled pADPr accumulation and PARP1/2-dependent cytotoxicity. Moreover, we demonstrated that proteins involved in Okazaki fragment ligation and/or base excision repair regulate pADPr signaling and cell death induced by PARG inhibition. In addition, we determined that PARG expression is critical for cellular sensitivity to PARG inhibition. Additionally, we revealed that PARG is essential for cell survival by suppressing pADPr. Collectively, our data not only identify an essential role for PARG in normal proliferating cells but also provide a potential biomarker for the further development of PARG inhibitors in cancer therapy.
- 5 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessDePARylation is critical for S phase progression and cell survival
Poly(ADP-ribose)ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation by poly(ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic regulation of DNA damage response. PARG, the most active dePARylation enzyme, is recruited to sites of DNA damage via pADPr-dependent and PCNA-dependent mechanisms. Targeting dePARylation is considered an alternative strategy to overcome PARP inhibitor resistance. However, precisely how dePARylation functions in normal unperturbed cells remains elusive. To address this challenge, we conducted multiple CRISPR screens and revealed that dePARylation of S phase pADPr by PARG is essential for cell viability. Loss of dePARylation activity initially induced S-phase-specific pADPr signaling, which resulted from unligated Okazaki fragments and eventually led to uncontrolled pADPr accumulation and PARP1/2-dependent cytotoxicity. Moreover, we demonstrated that proteins involved in Okazaki fragment ligation and/or base excision repair regulate pADPr signaling and cell death induced by PARG inhibition. In addition, we determined that PARG expression is critical for cellular sensitivity to PARG inhibition. Additionally, we revealed that PARG is essential for cell survival by suppressing pADPr. Collectively, our data not only identify an essential role for PARG in normal proliferating cells but also provide a potential biomarker for the further development of PARG inhibitors in cancer therapy.
- Open Access
- 2 March 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (9) , 686-703
Proteomic analysis of ferroptosis pathways reveals a role of CEPT1 in suppressing ferroptosis
Ferroptosis has been recognized as a unique cell death modality driven by excessive lipid peroxidation and unbalanced cellular metabolism. In this study, we established a protein interaction landscape for ferroptosis pathways through proteomic analyses, and identified choline/ethanolamine phosphotransferase 1 (CEPT1) as a lysophosphatidylcholine acyltransferase 3 (LPCAT3)-interacting protein that regulates LPCAT3 protein stability. In contrast to its known role in promoting phospholipid synthesis, we showed that CEPT1 suppresses ferroptosis potentially by interacting with phospholipases and breaking down certain pro-ferroptotic polyunsaturated fatty acid (PUFA)-containing phospholipids. Together, our study reveals a previously unrecognized role of CEPT1 in suppressing ferroptosis.
- 2 March 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 15 (9) , 686-703
Open AccessProteomic analysis of ferroptosis pathways reveals a role of CEPT1 in suppressing ferroptosis
Ferroptosis has been recognized as a unique cell death modality driven by excessive lipid peroxidation and unbalanced cellular metabolism. In this study, we established a protein interaction landscape for ferroptosis pathways through proteomic analyses, and identified choline/ethanolamine phosphotransferase 1 (CEPT1) as a lysophosphatidylcholine acyltransferase 3 (LPCAT3)-interacting protein that regulates LPCAT3 protein stability. In contrast to its known role in promoting phospholipid synthesis, we showed that CEPT1 suppresses ferroptosis potentially by interacting with phospholipases and breaking down certain pro-ferroptotic polyunsaturated fatty acid (PUFA)-containing phospholipids. Together, our study reveals a previously unrecognized role of CEPT1 in suppressing ferroptosis.
- Top Cited Papers
- 6 February 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (3) , 404-414
Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis
SLC7A11-mediated cystine uptake suppresses ferroptosis yet promotes cell death under glucose starvation; the nature of the latter cell death remains unknown. Here we show that aberrant accumulation of intracellular disulfides in SLC7A11high cells under glucose starvation induces a previously uncharacterized form of cell death distinct from apoptosis and ferroptosis. We term this cell death disulfidptosis. Chemical proteomics and cell biological analyses showed that glucose starvation in SLC7A11high cells induces aberrant disulfide bonds in actin cytoskeleton proteins and F-actin collapse in a SLC7A11-dependent manner. CRISPR screens and functional studies revealed that inactivation of the WAVE regulatory complex (which promotes actin polymerization and lamellipodia formation) suppresses disulfidptosis, whereas constitutive activation of Rac promotes disulfidptosis. We further show that glucose transporter inhibitors induce disulfidptosis in SLC7A11high cancer cells and suppress SLC7A11high tumour growth. Our results reveal that the susceptibility of the actin cytoskeleton to disulfide stress mediates disulfidptosis and suggest a therapeutic strategy to target disulfidptosis in cancer treatment.
- 6 February 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (3) , 404-414
Top Cited PapersActin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis
SLC7A11-mediated cystine uptake suppresses ferroptosis yet promotes cell death under glucose starvation; the nature of the latter cell death remains unknown. Here we show that aberrant accumulation of intracellular disulfides in SLC7A11high cells under glucose starvation induces a previously uncharacterized form of cell death distinct from apoptosis and ferroptosis. We term this cell death disulfidptosis. Chemical proteomics and cell biological analyses showed that glucose starvation in SLC7A11high cells induces aberrant disulfide bonds in actin cytoskeleton proteins and F-actin collapse in a SLC7A11-dependent manner. CRISPR screens and functional studies revealed that inactivation of the WAVE regulatory complex (which promotes actin polymerization and lamellipodia formation) suppresses disulfidptosis, whereas constitutive activation of Rac promotes disulfidptosis. We further show that glucose transporter inhibitors induce disulfidptosis in SLC7A11high cancer cells and suppress SLC7A11high tumour growth. Our results reveal that the susceptibility of the actin cytoskeleton to disulfide stress mediates disulfidptosis and suggest a therapeutic strategy to target disulfidptosis in cancer treatment.
- Open Access
- 13 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (19) , eabm6638
Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors
Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However, tumor suppressors cannot be directly targeted because of their loss of function. To uncover specific vulnerabilities for cells with deficiency in any given tumor suppressor(s), we performed genome-scale CRISPR loss-of-function screens using a panel of isogenic knockout cells we generated for 12 common tumor suppressors. Here, we provide a comprehensive and comparative dataset for genetic interactions between the whole-genome protein-coding genes and a panel of tumor suppressor genes, which allows us to uncover known and new high-confidence synthetic lethal interactions. Mining this dataset, we uncover essential paralog gene pairs, which could be a common mechanism for interpreting synthetic lethality. Moreover, we propose that some tumor suppressors could be targeted to suppress proliferation of cells with deficiency in other tumor suppressors. This dataset provides valuable information that can be further exploited for targeted cancer therapy.
- 13 May 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (19) , eabm6638
Open AccessGenome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors
Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However, tumor suppressors cannot be directly targeted because of their loss of function. To uncover specific vulnerabilities for cells with deficiency in any given tumor suppressor(s), we performed genome-scale CRISPR loss-of-function screens using a panel of isogenic knockout cells we generated for 12 common tumor suppressors. Here, we provide a comprehensive and comparative dataset for genetic interactions between the whole-genome protein-coding genes and a panel of tumor suppressor genes, which allows us to uncover known and new high-confidence synthetic lethal interactions. Mining this dataset, we uncover essential paralog gene pairs, which could be a common mechanism for interpreting synthetic lethality. Moreover, we propose that some tumor suppressors could be targeted to suppress proliferation of cells with deficiency in other tumor suppressors. This dataset provides valuable information that can be further exploited for targeted cancer therapy.
- Open Access
- 11 May 2022
- Published by Springer Nature in Research Square
Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis
Lysosomes play vital roles in the degradation and recycling of various macromolecules, protein secretion, energy metabolism, and cell signaling. Increasing evidence suggests that the deregulated lysosomes contribute to tumorigenesis and therapeutic resistance. However, its underlying mechanisms remain elusive. We herein identified transmembrane protein 9 (TMEM9) as a crucial protein modulating lysosomal metabolism and lysosome-associated signaling. The TMEM9 gene is markedly amplified in breast cancer, correlated with its transcriptional upregulation. TMEM9 depletion suppressed the proliferation of breast cancer cells highly expressing TMEM9. Consistently, Tmem9 knock-out inhibited mammary tumorigenesis in the genetically engineered mouse model. Conversely, the ectopic expression of TMEM9 in TMEM9 low breast cancer cells promoted cell proliferation. The lysosome purification and proteomics approach showed that TMEM9 physically and functionally interacts with LAMTOR4, a subunit of the Ragulator complex, to hyperactivate mTOR signaling in breast cancer. Moreover, the pharmacological blockade of the TMEM9-v-ATPase axis combined with mTOR inhibitors exhibited the synergistic growth inhibition of breast cancer cells. Our results reveal the mechanism of the TMEM9-v-ATPase-activated mTOR signaling and further propose the TMEM9-v-ATPase axis as a therapeutic target overcoming mTOR inhibitor resistance of breast cancer.
- 11 May 2022
- Published by Springer Nature in Research Square
Open AccessLysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis
Lysosomes play vital roles in the degradation and recycling of various macromolecules, protein secretion, energy metabolism, and cell signaling. Increasing evidence suggests that the deregulated lysosomes contribute to tumorigenesis and therapeutic resistance. However, its underlying mechanisms remain elusive. We herein identified transmembrane protein 9 (TMEM9) as a crucial protein modulating lysosomal metabolism and lysosome-associated signaling. The TMEM9 gene is markedly amplified in breast cancer, correlated with its transcriptional upregulation. TMEM9 depletion suppressed the proliferation of breast cancer cells highly expressing TMEM9. Consistently, Tmem9 knock-out inhibited mammary tumorigenesis in the genetically engineered mouse model. Conversely, the ectopic expression of TMEM9 in TMEM9 low breast cancer cells promoted cell proliferation. The lysosome purification and proteomics approach showed that TMEM9 physically and functionally interacts with LAMTOR4, a subunit of the Ragulator complex, to hyperactivate mTOR signaling in breast cancer. Moreover, the pharmacological blockade of the TMEM9-v-ATPase axis combined with mTOR inhibitors exhibited the synergistic growth inhibition of breast cancer cells. Our results reveal the mechanism of the TMEM9-v-ATPase-activated mTOR signaling and further propose the TMEM9-v-ATPase axis as a therapeutic target overcoming mTOR inhibitor resistance of breast cancer.